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Abstract
The MATRICS Consensus Cognitive Battery (MCCB) fills a significant need for a standardized 
battery of cognitive tests to use in clinical trials for schizophrenia in adults aged 20-59. A need 
remains, however, to develop norms for younger individuals, who also show elevated risks for 
schizophrenia. Toward this end, we assessed performance in healthy adolescents. Baseline MCCB, 
reading and IQ data were obtained from healthy controls (ages 12-19) participating in two 
concurrent NIMH-funded studies: North American Prodromal Longitudinal Study phase 2 
(NAPLS-2; n=126) and Boston Center for Intervention Development and Applied Research 
(CIDAR; n=13). All MCCB tests were administered except the Managing Emotions subtest from 
the Mayer-Salovey-Caruso Emotional Intelligence Test. Data were collected from 8 sites across 
North America. MCCB scores were presented in four 2-year age cohorts as T-scores for each test 
and cognitive domain, and analyzed for effects of age and sex. Due to IQ differences between age-
grouped subsamples, IQ served as a covariate in analyses. Overall and sex-based raw scores for 
individual MCCB tests are presented for each age-based cohort. Adolescents generally showed 
improvement with age in most MCCB cognitive domains, with the clearest linear trends in Speed 
of Processing, Attention/Vigilance, and Working Memory. These control data show that healthy 
adolescence is a dynamic period for cognitive development that is marked by substantial 
improvement in MCCB performance through the 12-19 age range. They also provide healthy 
comparison raw scores to facilitate clinical evaluations of adolescents, including those at risk for 
developing psychiatric disorders such as schizophrenia-related conditions.
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Neurocognitive impairments are a central problem for individuals with schizophrenia, 
beginning in childhood during the premorbid period and continuing throughout life. The 
development of a pathway for regulatory approval for new treatment strategies to reduce 
cognitive deficits in schizophrenia created the need for a standardized battery of 
neuropsychological tests to assess the effectiveness of proposed treatments. A National 
Institute of Mental Health (NIMH) initiative to encourage the development of novel 
interventions to attenuate cognitive deficits in schizophrenia, called Measurement and 
Treatment Research to Improve Cognition in Schizophrenia (MATRICS), addressed this 
need. This led to the development of a reliable, valid ―MATRICS Consensus Cognitive 
Battery‖ (MCCB) for use in clinical trials and for other purposes (Kern, et al., 2008; 
Nuechterlein, et al., 2008). The MCCB is comprised of 9 tests that reflect six distinct, 
replicated dimensions of neurocognitive dysfunction in schizophrenia, including: Speed of 
Processing, Attention/Vigilance, Working Memory, Verbal Learning, Visual Learning, and 
Reasoning and Problem Solving (Nuechterlein et al., 2004). A 10th test, the Managing 
Emotions Branch of the Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT), and 
the additional dimension, Social Cognition, was added because of growing interest in this 
component of function, and because of its relevance to real world function (Nuechterlein and 
Green, 2006).
Thus far, investigations into the psychometric properties of the MCCB have been positive. 
The MCCB demonstrates excellent reliability, minimal practice effects, a low rate of missing 
data and significant correlations with functional capacity measures (Green, et al., 2011; 
Nuechterlein, et al., 2008). Subsequent large, industry-sponsored, multi-site clinical trial 
studies have affirmed these positive psychometric characteristics (Buchanan, et al., 2011; 
Keefe, et al., 2011). The MCCB has also shown strong sensitivity to change in adults with 
schizophrenia who participated in an intensive cognitive remediation program (Fisher et al., 
2009).
Validation studies involving the MCCB have also been encouraging. Progress has been made 
in demonstrating that improvement on neuropsychological tests such as those in the MCCB 
is related to improvement in =real-world‘ tasks (Buchanan, et al., 2005; Buchanan, et al., 
2011). Methods for evaluating performance-based and interview-based measures were 
developed as part of the MATRICS Psychometric and Standardization Study (PASS) (Green, 
et al., 2008), and supported by the Validation of Intermediate Measures study (VIM) (Green, 
et al., 2011). The success of the MCCB has also been facilitated by its translation into many 
languages for use in international trials. Indeed, the MATRICS website (http://
www.matricsinc.org) listed 21 languages by 2015.
The initial success of the MCCB reliability and validity studies has spurred efforts to 
characterize the battery further and expand its utility. Recent investigations focused on 
efforts to refine its factor structure (Burton, et al., 2013; McCleery, et al., 2015), assess its 
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performance in other psychiatric conditions such as bipolar disorder (Burdick, et al., 2011; 
Sperry, et al., 2015), and evaluate its performance in older individuals (Rajji, et al., 2013). 
One area in particular need of further study is the performance of psychiatrically healthy 
adolescents on the MCCB. While the MCCB norms are stratified for age and sex, and cover 
the adult age ranges of 20-59 in five year intervals, a substantial proportion of people with 
schizophrenia experience the onset of their illness (Cannon, et al., 1999; Juuhl-Langseth et 
al., 2014; Thomsen, 1996) or associated, prodromal symptoms of their illness before age 20. 
The interpretation of the MCCB scores is thus limited in pharmacological and/or 
psychosocial clinical trials involving youth. Individuals with early-onset schizophrenia 
(EOS; onset before age 18), including childhood onset (COS; onset by age 13) and 
adolescent-onset schizophrenia (AOS; onset between ages 13-18), constitute an important 
clinical population, particularly for early intervention.
There are additional reasons to study cognitive functions in this younger age group. First, the 
identification of cognitive problems is significant in its own right, regardless of etiology. 
Second, it is often prognostic, especially in clinical high risk (CHR) adolescent samples 
(Fusar-Poli, Borgwardt, et al., 2012; Fusar-Poli, Deste, et al., 2012; Giuliano, et al., 2012; 
Seidman, et al., 2010; Woodberry et al., 2008). Moreover, cognitive weaknesses often 
predict current function in high risk youth (Lin, et al., 2011), rates of premorbid 
abnormalities, familial schizophrenia-spectrum disorders (Nicolson, et al., 2003), subsequent 
exacerbations of cognitive problems (Rajji et al., 2009), greater social disability (Eggers and 
Bunk, 1997) and functional outcomes over time (Amminger, et al., 2011; Ballageer et al., 
2005; Hollis, 2000; Insel, 2007, 2010).
It is thus important to clearly interpret MCCB performance in healthy individuals younger 
than 20, and particularly in adolescents. Among the few published studies using the MCCB 
in patients with schizophrenia-spectrum disorders and healthy control subjects below the age 
of 18, adolescents aged 11-13 years old who showed symptoms of psychosis performed 
more poorly on several MCCB tasks than adolescents who did not show psychotic 
symptoms (Kelleher et al., 2013). Similarly, adolescents 12 to 18 years old with 
schizophrenia-spectrum disorders (mean=15.8 years) showed stable performance deficits 
compared to age-matched healthy controls on all MCCB domains except social cognition 
(Holmen et al., 2010; Juuhl-Langseth, et al., 2014).
Still needed, however, are studies of MCCB performance across normal development, both 
to identify developmental trajectories, and to establish useful comparison data for 
researchers and clinicians. A Norwegian standardization project reported progress towards 
this goal by measuring MCCB performance for 5 groups ranging from 12 to 59 years of age, 
including a 12 to 19 year-old group (n=50) (Mohn et al., 2012). Similarly, a recent study 
assessed MCCB performance in 5 groups ranging from 8 to 23 years of age and narrowed 
the age bands to 4-year bins (e.g. 8 to 11 years; n‘s=21 to 54 for the 3 adolescent bins) 
(Nitzburg, et al., 2014). This study provided raw scores and T-scores, the latter of which 
were derived across all age groups. While both of these studies assessed adolescents, they 
covered this dynamically complex and heterogeneous stage of development as either a single 
eight-year period (Mohn, et al., 2012), or as 3 four-year periods that also included younger 
children in the earlier period and adults older than 19 in the later period (Nitzburg, et al., 
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2014). The current study extends the analysis of normal MCCB performance by focusing 
solely on a teenage sample to assess age-related differences within adolescence, with data 
presented in 4 two-year age periods that range from ages 12 to 19, further refining healthy 
comparison data for this period.
We present adolescent control data and examine the influence of age and sex on test 
performance, comparing our findings with those described in the original adult (aged 20-59) 
version. Our goal is to expand the utility of the MCCB as a standard battery for adolescents 
by providing both developmental trajectories for each of its cognitive domains (except social 
cognition), and control comparison data as raw scores to facilitate clinical evaluations of 
adolescents who may be at risk for developing psychiatric disorders.
METHODS
Participants
Participants included 139 adolescents and young adults between the ages of 12-19 who were 
recruited as healthy control (HC) volunteers from two concurrent NIMH-funded studies: the 
second phase of the multi-site North American Prodromal Longitudinal Study (NAPLS-2; 
n=126; 91% of the overall sample, which included eight sites from four geographic regions), 
and the single-site Boston Center for Intervention Development and Applied Research 
(CIDAR) study, ―Vulnerability to Progression in Schizophrenia‖ (n=13; 9% of the overall 
sample). The studies evaluated the same age ranges and comparison groups (i.e., CHR 
youth), during the same time period (2007-2012), and it thus seemed justified to combine 
them. Study inclusion and exclusion criteria were similar for the two studies, and are 
summarized in Table 1.
All study participants (or legal guardians for those under 18) gave written informed consent 
prior to study participation. Participants under 18 provided assent. The NAPLS-2 study was 
approved by institutional review boards (IRBs) at all NAPLS-2 sites (Emory University, 
Harvard University/Beth Israel Deaconess Medical Center, University of California Los 
Angeles, University of California San Diego, University of Calgary, University of North 
Carolina, Yale University, and Zucker Hillside Hospital). The CIDAR study was approved 
by local Boston IRB committees at Harvard Medical School, Beth Israel Deaconess Medical 
Center, Massachusetts General Hospital, and Brigham and Women‘s Hospital.
Neuropsychological Measures
Intelligence was estimated with the Vocabulary and Block Design subtests of the Wechsler 
Abbreviated Scale of Intelligence-I (WASI-I) (Wechsler, 1999), and word reading skills were 
estimated with the Word Reading subtest of the Wide Range Achievement Test-4 (Wilkinson 
and Robertson, 2006). The MCCB (Kern, et al., 2008; Nuechterlein and Green, 2006) was 
administered as part of larger neuropsychological assessments in the NAPLS and CIDAR 
studies. Nine of 10 MCCB tests were administered to all participants. The Managing 
Emotions subtest of the MSCEIT (Mayer et al, 2002) was excluded because its validity for 
subjects as young as age 12 was not established and alternative measures of social cognition 
were used in the studies. The six cognitive domains and nine tests are shown in Table 2.
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Statistical analyses were performed with IBM SPSS Statistics, Version 20 (IBM 
Corporation, Somers, NY). To support direct comparison with the original MCCB co-
norming and standardization study (Kern, et al., 2008), we largely adopted the same data 
analytic procedures, with some exceptions. We were not able to compute a social cognition 
domain score and overall composite score given that the MSCEIT subtest was not 
administered. Moreover, due to significant IQ differences between age groups (described 
below), we employed IQ as a covariate in subsequent analyses. This modification from the 
procedure used to norm the MCCB in adults allowed us to address our central goal of 
assessing its domain-specific cognitive effects beyond the level of generalized cognitive 
effects (i.e. IQ) more clearly. This approach is consistent with evidence that generalized and 
more specific cognitive effects are separable in schizophrenia (Mohn et al., 2014b; 
Nuechterlein, et al., 2004). It may be particularly useful more generally in developmental 
periods characterized by larger cognitive performance differences than are typically present 
in young and middle adulthood, such as adolescence and aging (Rentz, et al., 2004; Rentz, et 
al., 2007; Steinberg, Smith et al., 2005; Steinberg, Bieliauskas et al., 2005).
As with Kern et al., raw scores for each of the 9 MCCB tests administered were examined 
for normality of distribution (Kern, et al., 2008). Any distributions that were notably skewed 
were logarithmically transformed. Raw or transformed scores were standardized to T scores 
(mean = 50, SD = 10) based on the overall sample of 139 participants. Summary scores for 
cognitive domains that included more than one measure were computed by summing the T 
scores of the tests in those domains and standardizing the sums to T scores. The T scores 
were analyzed to examine age, sex, and education effects. Differences in performance across 
the six cognitive domains were assessed using analyses of covariance (ANCOVAs). Follow-
up contrasts were conducted for significant ANCOVAs, with a p value <0.05 considered 
statistically significant.
RESULTS
Several distributions of the nine MCCB tasks were skewed and thus transformed as 
described above. Logarithmically transformed variables included Trail Making Test Part A 
(following which the direction of the log scores was reversed before T-score conversion), 
HVLT-R, BVMT-R, and NAB Mazes. Sociodemographic and other characteristics of the 
overall sample and age cohorts are provided in Table 3. The age range from 12 to 19 
provides coverage of the adolescent period of development up to the lower boundary of the 
MCCB standardization sample. Because age effects are typically substantial for most 
cognitive tests during the rapid neurodevelopment of the childhood and adolescent periods, 
age was used as the primary stratification variable. However, because this healthy control 
sample was ascertained to match CHR or first episode (FE) psychosis clinical subjects 
within their respective studies, and was not collected for purely normative purposes, the 
sample sizes varied across age cohorts with ns ranging from 10 to 22. Due to relatively low 
sample sizes within some individual one-year age bands, participants were grouped into 
two-year age increments. Participants‘ age ranged between 12.1 and 19.9 years, with a mean 
of 16.3 years (SD = 2.2). Given the significant difference in estimated WASI IQ between the 
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four age groups (F (3, 135) = 5.02, p = .002), as noted above, IQ was used as a covariate in 
all analyses of MCCB T-score differences. Tables 4 and 5 provide cognitive domain T-score 
and test raw score means and standard deviations by 2-year age cohort, respectively. Figure 
1 displays age-referenced performance levels for each of the six cognitive domains. 
Furthermore, in line with procedures detailed previously for the MCCB scoring program 
(Kern, et al., 2008), regression-based T-scores are presented for all cognitive domains in 
Supplemental Table 3.
Performance level significantly increased with age in all cognitive domains except for Verbal 
and Visual learning (Speed of Processing: F (3, 130) = 9.34, p < .0001; Attention/Vigilance: 
F (3, 125) = 10.61, p < .0001; Working Memory: F (3, 130) = 7.44, p < .0001; Verbal 
Learning: F (3, 130) = 1.17, p = .32; Visual Learning: F (3, 130) = 2.37, p = .07; Reasoning 
and Problem-Solving: F (3, 130) = 4.47, p = .005). Follow-up polynomial contrasts for the 
domains showing significant age effects revealed significant quadratic trends for Speed of 
Processing (p = .004) and Reasoning and Problem-Solving (p = .005), and significant linear 
trends for Attention/Vigilance (p < .0001) and Working Memory (p < .0001). These results 
suggest that while there were generally significant incremental improvements in 
performance with age across these domains, there was some leveling off in performance 
with increased age for Speed of Processing and Reasoning and Problem-Solving. For the 
regression-based T-scores, there were similar significant quadratic trends for Speed of 
Processing (p = .003) and Reasoning and Problem-Solving (p = .004), but there were no 
significant trends observed for Attention/Vigilance and Working Memory.
Sex and educational level were also considered as stratification variables. The majority of 
the overall sample was male (n = 83; 60%), ascertained to be comparable on sex ratios to 
CHR and FE case samples which tend to have more males than females. This contrasts with 
the MCCB adult standardization sample, which was 53% female. For the overall sample (n = 
139), significant sex effects were present only for the Reasoning and Problem-Solving 
domain (t (142) = 3.24, p = .002), with males outperforming females. Thus, Reasoning and 
Problem-Solving Domain scores are stratified by age and sex (see Tables 2 & 3). Overall 
performance on cognitive domains (T-scores) and individual tests (raw scores) are provided 
along with sex-specific mean scores in Supplemental Tables 1 and 2, respectively.
As expected, given our school age sample, age and education were highly correlated (r = .
96). Thus, in contrast to adult samples that benefit from stratification by education to control 
for education effects on cognitive test performance, we present our data by age group only. 
As displayed in Table 3, the average level of education for the overall sample was 9.8 years 
(SD = 2.2), with a range of 5-14 years.
A majority of the overall sample was right hand dominant (n = 122, 87.8%). Notably, the 
overall sample demonstrated an estimated WASI Full Scale IQ which falls on the cusp of the 
average and high average ranges (M = 109.3, SD = 15.4). This pattern is largely consistent 
with the IQ levels of many healthy control samples ascertained in clinical research studies, 
and is likely due to the selection biases that influence study participation (in contrast to 
census-referenced or population-based standardization studies). Moreover, the IQs of the 
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CHR and FE samples were in this range, and controls were selected to be in the same IQ 
range on average.
DISCUSSION
These findings show that performance in MCCB cognitive domains follows a dynamic 
trajectory of improvement in adolescent NAPLS and CIDAR control subjects that is at least 
partially independent of overall cognitive ability (i.e. IQ). They also show means and 
standard deviations for individual test scores throughout adolescence. These data add to a 
small literature describing the performance of healthy individuals below the age of 20 on the 
MCCB. It is the first study to focus on adolescents specifically, with performance data 
provided in the relatively narrow 2-year age bins between the ages of 12 and 19. The use of 
standardized T-scores in the 8-year period under study increases the sensitivity to detect 
normal, age-related cognitive performance differences in adolescence. The current study 
also includes the most geographically diverse sample of MCCB performance in adolescents 
collected to date, with data obtained from eight sites across North America.
The results show that after controlling for IQ in all analyses, performance in each cognitive 
domain, except verbal and visual learning, significantly increased with age, as expected (see 
Fig. 1). Consistent with Nitzburg et al (2014), who also showed general cognitive 
improvement with age, most domains (4 out of 6) demonstrated larger improvements at the 
younger end of the age range (i.e. between the 12-13 and the 14-15 year-old groups). 
Continued improvements were also evident for most domains (also 4 out of 6), into the 
oldest age group (18-19 years old). Both of these trends underscore the point that normal 
adolescence is a dynamic period of cognitive development that may be delineated most 
accurately by multiple assessment points at different ages, as some tests may not 
demonstrate maturational plateaus until late adolescence or early adulthood. Consistent with 
Nitzburg et al, sex effects were quite modest. In both studies, males (collapsed across age 
groups) showed significantly better performance on the Reasoning and Problem-Solving 
task (NAB Mazes), though Mohn and colleagues did not observe significant gender 
differences in their 12-19 year old subjects (Mohn, et al., 2012; Mohn et al., 2014a). Our 
significant sex effects for Reasoning and Problem-Solving were observed within each age 
band except for the 14-15 year old group. It should be noted that our sample and that of 
Nitzburg et al differed demographically from that of Mohn et al, particularly in showing 
higher levels of racial and ethnic heterogeneity, though it is unclear whether those factors 
interacted with gender to produce different cognitive performance profiles. It is also 
noteworthy that the Reasoning and Problem Solving task in the MCCB is a visuospatial one, 
which might favor males (Quaiser-Pohl and Lehmann, 2002).
The T-scores in the current study were derived from the current sample for the purpose of 
showing normal developmental trajectories in adolescents using the same method as the 
MCCB (Kern, et al., 2008). Mean performance T-scores could thus not serve as normative 
values for other samples in educational, clinical or other applied contexts, as they were not 
standardized within each age group, but were instead standardized across gender and all age 
groups. For normative purposes, mean raw scores for all MATRICS‘ tests are presented for 
each age of the 4 adolescent age ranges in Table 3. Raw scores are also presented in 
Stone et al. Page 8













Supplemental Table 2, with sex specific norms for each age band to allow clinicians or 
researchers to identify the most appropriate comparison reference data. Dividing the sample 
by sex lowered the subject numbers in the 3 older groups to between 12 and 24 subjects, 
with the lower cell sizes comprising the female subjects. The overall number of subjects in 
the youngest group (12-13 year-olds) was smaller than the other groups (n=24, compared to 
37, 39 and 39), however, and included only 6 females. Thus, while this Table may still be 
useful for estimates of sex-related differences in each age band, the relatively low number of 
subjects in each cell, particularly in the 12-13 year old group, renders interpretations of 
performance values for each sex much more tentative than healthy comparison values based 
on age alone.
As Table 3 demonstrated, most demographic measures assessed in this study did not differ 
by age. The WASI IQ score was an important exception, and was thus used as a covariate in 
subsequent analyses. Notably, adolescent, age-related differences in MCCB performance 
remained robust, which underscores the point that while general cognitive ability (e.g. IQ) 
and other cognitive domains are typically related to each other in healthy samples, they are 
also separable (e.g. Heyanka et al., 2013; Mohn, et al., 2014b; Wechsler, 1997). The 
generally progressive improvement in MCCB performance during development in healthy 
adolescents, which was at least partially independent of general cognitive abilities, supports 
the view established in adult MCCB studies that test performance is influenced differentially 
by multiple, at least partially separable factors (Nuechterlein, et al., 2004; Nuechterlein, et 
al., 2008).
Several recent studies that employed the MCCB in schizophrenia or related conditions in 
adolescents showed evidence that cognitive dysfunctions are also subject to at least partially 
separable factors. Among these, Holmen et al (2010) showed evidence for both a generalized 
cognitive deficit (all MCCB test scores were significantly lower in a schizophrenia-spectrum 
group aged 12 to 18 years old than in a control group, except for the MSCEIT, which did not 
differ between groups) and for relatively more severe or milder deficits in individual 
cognitive domains. The same group also assessed a sample of schizophrenia-spectrum 
patients aged 12 to 18 at baseline and then 1 and 2 years later, and showed significant 
impairment on all MCCB cognitive domains at each time point, compared to healthy 
controls (Juuhl-Langseth, et al., 2014). Kelleher et al (2013), studying an extended 
schizophrenia phenotype in a sample of community-dwelling schoolchildren aged 11 to 13 
years old who reported psychotic symptoms, showed MCCB performance deficits (versus a 
group of students who did not report psychotic symptoms) that were limited to processing 
speed (TMT-A and SC-BACS) and working memory (WMS-III SS). Of note, Juuhl-
Langseth et al reported a mean age of 15.6 years for their schizophrenia spectrum subjects, 
and Holmen et al. reported a mean age of 15.8. The mean age of the total current sample was 
16.3, which is similar. Inspection of the patient MCCB scores in both patient groups shows 
poorer performance on all MCCB measures than the healthy subjects in the current study 
(Table 5).
Thus, at this point, the available literature suggests that the MCCB may be sensitive to the 
development of both generalized and more specific cognitive deficits in schizophrenia-
related conditions in adolescence, as it is in adults. Both because schizophrenia or related 
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conditions may onset in adolescence, and also because cognitive deficits often begin in 
childhood or adolescence and precede the development of psychosis, it is essential to extend 
the normative foundation of MCCB performance to cover this critical developmental period 
marked by escalating vulnerability to first-episode psychiatric disorders. Such efforts will 
facilitate the development or refinement of treatment efforts, and early intervention and 
preventive efforts as well. In this context, the current findings add to the literature 
establishing the utility of the MCCB as a standard battery for clinical trials of cognitive-
enhancing treatments for adolescent-onset schizophrenia, and also for schizophrenia-related 
conditions that manifest themselves in this period either before the onset of psychosis, or in 
its absence. Similarly, these healthy comparison data in adolescence contribute to the 
validation of the MCCB as a clinical battery to facilitate both assessment and intervention 
efforts. Finally, our findings also underscore the dynamic nature of adolescence, and the 
need for larger, population-based studies to establish normative performance values at 
multiple ages and in the context of multiple demographic influences on cognitive function.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Mean T-scores of MCCB cognitive domains by age group
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Table1
NAPLS-2 and CIDAR Inclusion/Exclusion Characteristics for Control Participants
Variable NAPLS-2 CIDAR
Adolescent Age Range 12-19 13-19
Screening for Axis I DSM-IV-
TR Disorders
Structured Clinical Interview (SCID) for DSM-IV-TR, Non-
patient edition (First, Spitzer, Gibbon, & Williams, 2002) for
ages ≥18, or the Kid-SCID (Hien, et al., 1994) for subjects 13-
17 years of age,
Assessment of Prodromal
Symptoms and Syndromes
Structured Interview for Prodromal Syndromes; (Miller, et al.,
2003)
Exclusion Criteria   Current or past major DSM-IV-TR Axis I disorder,
prodromal syndrome, schizotypal or other Cluster A personality
disorders, significant traumatic brain injury or other central
nervous system disorder, sensory motor handicaps interfering
with test taking, psychiatric hospitalizations, history of
electroconvulsive therapy, a first degree relative with psychosis,
current or past use of antipsychotic medications, other
psychotropic medication use within 6 months of study
participation (except sleep medications or anxiolytic agents), IQ
< 70, lack of fluency in English, DSM-IV-TR substance abuse
in the past month or dependence in the last 3 months (excluding
nicotine), current suicidality.
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Table 2
MCCB Cognitive Domains and Tests
COGNITIVE DOMAIN TEST
Speed of Processing Category fluency/verbal fluency for animals
(CF) (Blair & Spreen, 1989)
Symbol coding subtest from the Brief
Assessment of Cognition in Schizophrenia
(SC-BACS) (Keefe, et al., 2004)
Trail Making Test- Part A (TMT-A) (United
States War Department, 1944)
Attention/Vigilance Continuous Performance Test-Identical Pairs
(CPT-IP) (Cornblatt, Risch, Faris, Friedman, &
Erlenmeyer-Kimling, 1988)
Working Memory University of Maryland—Letter-Number Span
(LNS) (Gold, Carpernter, Randolph, Goldberg,
& Weinberger, 1997)
Spatial Span subtest from the Wechsler
Memory Scale-III (WMS-III SS) (Wechsler,
1997b)
Verbal Learning Hopkins Verbal Learning Test- Revised
(HVLT-R) immediate recall (Brandt &
Benedict, 2001)
Visual Learning Brief Visuospatial Memory Test-Revised
(BVMT-R) (Benedict, 1997)
Reasoning and Problem Solving Mazes subtest from the Neuropsychological
Assessment Battery (NAB Mazes) (White &
Stern, 2003)
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Table 3














Age M (SD) 13.1 (0.6) 14.9 (0.6) 17.0 (0.5) 19.1 (0.6) 16.3 (2.2)





6.8 (0.9) 8.4 (0.9) 10.4 (0.8) 12.5 (0.6) 9.8 (2.2)
Median Parental Education
Levelb
7.0 7.0 7.0 7.0 7.0
Median Household Income
c 6.0 5.0 6.0 5.0 5.5
Race: Caucasian N (%) 15 (63%) 23 (62%) 18 (46%) 23 (59%) 79 (57%)
Ethnicity: Non-
Hispanic/Latino N (%)
22 (92%) 29 (78%) 32 (82%) 33 (85%) 116 (84%)
Handedness Right N (%) 24 (100%) 34 (92%) 31 (80%) 33 (85%) 122 (88%)
WASI FSIQ
a,d


























Note: All sites contributed to each 2-year age band except for the 12-13 year olds for whom none came from the
University of North Carolina.
*
ns vary by variable; actual n indicated in notes for superscript letters b and c below.
a
Significant age group differences were found for WASI FSIQ (p =0.002) and education (p < .001); Participant age and education level are highly 
correlated (r = 0.96).
b
Highest level of education achieved by participant’s mother or father. 6: some college/technical school/undergraduate education; 7: completed 
college/technical school/ undergraduate education; 8: some graduate/professional school; ns: 23, 35, 38, 38, and 134 left to right across columns.
c
Median Household Income: 5: $60,000-99,999, 6: $100,000 and above. ns: 24, 33, 37, 32, and 126 left to right across columns.
d
Wechsler Abbreviated Scale of Intelligence (WASI) Full Scale IQ estimate is based on administration of two subtests: Vocabulary and Block 
Design.
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Table 4































Working Memory 44.8 (8.6) 47.2(8.6) 50.8 (10.3) 55.0 (9.5) 50 (10)
Verbal Learning 49.4 (11.4) 48.9 (9.5) 47.5 (10.4) 53.9 (8.3) 50 (10)




45.6 (10.1) 49.7 (8.8) 51.6 (10.6) 51.4 (10.0) 50 (10)
*










Significant overall group sex differences were found for this cognitive domain (p < .001).
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Table 5


















TMT: Part A 33 6(14.7) 28.2 (10.3) 26.8 (10.1) 23.5 (10.0) 27.4 (11.4)
BACS Symbol Coding 52.9 (10.1) 58.5 (10.3) 64.7 (10.9) 66.6 (13.0) 61.6 (12.2)
HVLT-R† 26.7 (4.8) 26.7 (4.3) 25.9 (4.9) 29.0 (3.1) 27.1 (4.4)
WMS-II Spatial Span 15.8 (2.8) 17.3 (3.2) 17.8 (3.4) 18.5 (3.2) 17.5 (3.3)
Letter-Number Span 14.5 (3.1) 14.3 (2.8) 15.7 (3.4) 17.3 (3.1) 15.6 (3.3)
NAB Mazes† 18.4 (5.4) 20.7 (3.8) 21.0 (5.3) 21.2 (4.2) 20.5 (4.7)
BVMT-R 25.3 (6.9) 27.5 (4.1) 27.5 (5.5) 27.5 (5.6) 27.1 (5.5)
Category Fluency:
Animal Naming
22.3 (5.5) 23.5 (5.7) 24.5 (5.3) 25.2 (4.8) 24.0 (5.3)










TMT = Trail Making Test; BACS = Brief Assessment of Cognition in Schizophrenia; HVLT-R = Hopkins Verbal Learning Test-Revised; WMS: 
Wechsler Memory Scale; NAB = Neuropsychological Assessment Battery; BVMT-R = Brief Visuospatial Memory Test-Revised; CPT-IP = 
Continuous Performance Test – Independent Pairs.
d1 (d prime): = target/nontarget discrimination during vigilance
*










Significant overall group gender difference
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